PMID- 23924539
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20130808
IS  - 0025-7680 (Print)
IS  - 0025-7680 (Linking)
VI  - 73
IP  - 4
DP  - 2013
TI  - [Genetic tools for risk-stratification in multiple myeloma].
PG  - 369-75
AB  - Genetic studies have a central role in the study of multiple myeloma (MM), as 
      they become a critical component in the risk-based stratification of the disease. 
      Significant efforts have been made to identify genetic changes and signatures 
      that can predict clinical outcome and include them in the routine clinical care. 
      Fluorescence in situ hybridization (FISH) still remains the most used genetic 
      technique in clinical practice, mostly due to its very straightforward 
      implementation and the simplicity of data analysis. The advent of high-resolution 
      genomics (i.e. array CGH, exome and whole genome sequencing) and transcriptomics 
      tests (i.e. gene expression profiling - GEP, and mRNA sequencing) provide a 
      comprehensive analysis of the already defined genetic prognostic factors and are 
      helpful tools for the identification of potential novel disease markers on the MM 
      tumor clone. Indeed, GEP has been successfully implemented in MM as a 
      risk-stratification tool, holding the greatest power in outcome discrimination. 
      Nevertheless, some technical and logistic intricacies (need of a highly purified 
      tumor clone, cost of the assay and complexity of data analysis) need to be 
      considered before the definitive incorporation of high-throughput technologies in 
      routine clinical tests. Until then, FISH remains the standard tool for genomic 
      abnormality detection and disease prognostication.
FAU - Braggio, Esteban
AU  - Braggio E
AD  - Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
FAU - Albarracin Garramuno, Flavio
AU  - Albarracin Garramuno F
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - El uso de alteraciones geneticas en la estratificacion por riesgo del mieloma 
      multiple.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
SB  - IM
MH  - Gene Expression Profiling/methods
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Multiple Myeloma/diagnosis/*genetics
MH  - Prognosis
MH  - Risk Assessment/*methods
MH  - Translocation, Genetic
OTO - NOTNLM
OT  - genetic tools
OT  - multiple myeloma
OT  - risk-stratification
EDAT- 2013/08/09 06:00
MHDA- 2014/06/24 06:00
CRDT- 2013/08/09 06:00
PHST- 2013/08/09 06:00 [entrez]
PHST- 2013/08/09 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
PST - ppublish
SO  - Medicina (B Aires). 2013;73(4):369-75.